Hologic, Inc. $HOLX Shares Sold by Groupama Asset Managment

Groupama Asset Managment reduced its position in Hologic, Inc. (NASDAQ:HOLX) by 32.8% in the 3rd quarter, Holdings Channel reports. The fund owned 14,739 shares of the medical equipment provider’s stock after selling 7,203 shares during the period. Groupama Asset Managment’s holdings in Hologic were worth $995,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Invesco Ltd. lifted its position in Hologic by 72.5% during the second quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider’s stock worth $543,486,000 after buying an additional 3,505,828 shares during the period. Becker Capital Management Inc. boosted its stake in Hologic by 20.0% in the 3rd quarter. Becker Capital Management Inc. now owns 81,755 shares of the medical equipment provider’s stock worth $5,518,000 after buying an additional 13,610 shares during the last quarter. Natixis Advisors LLC grew its holdings in Hologic by 23.4% in the 3rd quarter. Natixis Advisors LLC now owns 437,338 shares of the medical equipment provider’s stock valued at $29,516,000 after buying an additional 82,894 shares during the period. Illinois Municipal Retirement Fund increased its stake in shares of Hologic by 20.4% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 172,294 shares of the medical equipment provider’s stock valued at $11,628,000 after acquiring an additional 29,143 shares during the last quarter. Finally, Readystate Asset Management LP acquired a new position in shares of Hologic during the 3rd quarter valued at about $4,161,000. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Stock Performance

NASDAQ HOLX opened at $75.41 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 4.04 and a quick ratio of 3.32. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $75.75. The firm has a market capitalization of $16.83 billion, a P/E ratio of 31.42, a P/E/G ratio of 2.24 and a beta of 0.73. The business’s 50-day simple moving average is $75.16 and its 200-day simple moving average is $72.93.

Hologic (NASDAQ:HOLX) last posted its earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). Hologic had a return on equity of 19.58% and a net margin of 13.18%.The business had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same period last year, the company posted $0.87 EPS. The firm’s revenue for the quarter was up 2.5% compared to the same quarter last year. Equities analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on HOLX. Evercore cut shares of Hologic from an “outperform” rating to an “in-line” rating and decreased their target price for the stock from $79.00 to $78.00 in a research report on Monday, January 5th. BNP Paribas Exane lowered shares of Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 price target for the company. in a research report on Friday, November 21st. Weiss Ratings reiterated a “hold (c)” rating on shares of Hologic in a report on Wednesday, January 28th. Finally, Argus cut shares of Hologic from a “buy” rating to a “hold” rating in a research note on Monday, January 12th. Two equities research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $78.42.

Hologic Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.